Broad Spectrum UVA / UVB Sunscreen Offers Eight Hours of Photostability
VANCOUVER, April 30, 2019 /CNW/ - Ovation Science Inc. (CSE: OVAT) ("Ovation" or the "Company"), a topical and transdermal cannabis product development company with a patented skin delivery technology and backed by over twenty years of research and development, today announced it has received the results of its successful completion of independent testing of its broad spectrum CBD sunscreen to be sold under its recently announced ARLO Beauty brand of skincare and anti-aging products.
There are two very important claims that a sunscreen can make: broad spectrum and water resistance. The SPF value of a sunscreen refers to protection from UVB rays. A sunscreen however that is "broad spectrum" means the sunscreen provides protection from both UVB as well as UVA rays; protecting the skin from ultraviolet rays that penetrate deeper, go through glass and clouds and can cause more severe skin damage. Only sunscreens with a critical wavelength above 370 nm are allowed to make the claim that they provide UVA protection. Ovation's ARLO Beauty sunscreen surpasses this criterion, allowing it to be labeled as having "broad spectrum" UVA and UVB protection. In addition, this independent testing also validated that Ovation's sunscreen achieved the highest level of water resistance allowed; 80 minutes.
The essential benefits of Ovation's sunscreen formulation are derived from its patented Invisicare® delivery technology. Along with the claims mentioned, ARLO Beauty sunscreen is also protected by a US patent for stabilizing sun filters (United States Patent and Trademark Office: "Sunscreen Composition with Enhanced UVA Absorber Stability and Methods", Patent Number 8128913). The sun filter avobenzone typically breaks down in the sun in less than two hours. Ovation's sunscreen formulation was granted a US patent as studies verified that it stabilized avobenzone for over eight hours, a unique advantage for ARLO Beauty sunscreen. (https://ovationscience.com/arlo-beauty-sunscreen)
"What distinguishes Ovation's products from other topical products on the market is our science, and this recent completion of independent testing of our ARLO Beauty CBD sunscreen is just further proof of that," said Doreen McMorran, Chief Operating Officer of Ovation. "Our sunscreen can not only make the highest claims allowed by the FDA: broad spectrum and 80 minutes water resistance, it is patent protected. This is an amazing product! People are going to love our sunscreen because it works phenomenally well, it doesn't run in your eyes, it doesn't make you sweat because your skin can still breathe and it's enhanced with the power of CBD. We believe this product will be a winner in the important sun care market, especially for those who do outdoor activities for hours in the sun like golfing, cycling or swimming."
BENEFITS OF ARLO BEAUTY SUNSCREEN - SPF 30 BROAD SPECTRUM
- Protects from harmful UVA and UVB rays (Broad Spectrum validated)
- 80 minute water resistance (The highest FDA designation obtainable)
- Glides on smoothly without any residue
- Won't run or perspire into your eyes
- No alcohol / No parabens / No fragrances
- Your skin can still breathe
The Company recently unveiled the launch of its new topical skincare product line infused with hemp-derived cannabidiol ("CBD") called ARLO Beauty (https://ovationscience.com/arlo-beauty/). This sunscreen, which will be the fifth product in the ARLO Beauty product line, is entering the US sun care market which is forecasted to reach US$2.7 billion by 2025 (Source: Grand View Research). In addition, the Company also recently announced the formation of an International Medical Dermatology Advisory Board focused on Ovation's scientific and product development. These key dermatology-focused opinion leaders will provide the Company with their expertise in topical dermatology-focused products while assisting in clinical studies.
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal cannabis and hemp formulations made with patented Invisicare® skin delivery technology. The technology enhances the delivery of cannabidiol (CBD) and tetrahydrocannabinol (THC) to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal cannabis products incorporating CBD, THC and combination products along with a line of anti-aging / beauty products made with CBD. Ovation's business model is to develop product formulations powered by Invisicare® and market directly to consumers as well as license-out these topical and transdermal formulations to cannabis companies globally. Ovation earns income from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.
Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
SOURCE Ovation Science Inc.
For further information: FOR INVESTOR RELATIONS: Dave Ryan, [email protected], Phone: 604-283-0903 ext. 2; FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES: Doreen McMorran, [email protected], Phone: 604.283.0903 ext. 4